Recombinant activated factor VII: 30 years of research and innovation

Blood Reviews

Volumn 29, Issue S1, 2015, Pages S4-S8

  Hedner, Ulla ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Acquired haemophilia; Congenital factor VII deficiency; Glanzmann's thrombasthenia; Haemophilia; Haemophilia with inhibitors; Recombinant activated factor VII in haemostasis

Indexed keywords

BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 7A INHIBITOR; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; PLACEBO; RECOMBINANT BLOOD CLOTTING FACTOR 7A; THROMBIN; THROMBOPLASTIN; RECOMBINANT FVIIA; RECOMBINANT PROTEIN;

ARTICLE; BLEEDING; BLOOD CLOTTING; BLOOD CLOTTING FACTOR 7 DEFICIENCY; BLUNT TRAUMA; BRAIN HEMORRHAGE; DOSE RESPONSE; DRUG BINDING; DRUG DOSE COMPARISON; DRUG MECHANISM; DRUG RESEARCH; GLANZMANN DISEASE; HEMOPHILIA; HEMOSTASIS; HUMAN; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SINGLE DRUG DOSE; THROMBOCYTE; THROMBOEMBOLISM; ANIMAL; HEMOPHILIA A;

ANIMALS; FACTOR VIIA; HEMOPHILIA A; HUMANS; RECOMBINANT PROTEINS;

EID: 84931478113     PISSN: 0268960X     EISSN: 15321681     Source Type: Journal    
DOI: 10.1016/S0268-960X(15)30002-3     Document Type: Article

References (78)

1. Hedner U, Brun NC Recombinant factor VIIa (rFVIIa): its potential role as a hemostatic agent. Neuroradiology 2007, 49:789-793.
2. Ahlberg A Haemophilia in Sweden. VII. Incidence, treatment and prophylaxis of arthropathy and other musculo-skeletal manifestations of haemophilia A and B. Acta Orthop Scand Suppl 1965, Suppl. 77:3-132.
3. Nilsson IM, Blomback M, Ahlberg A Our experience in Sweden with prophylaxis on haemophilia. Bibl Haematol 1970, 34:111-124.
4. DiMichele DM, Hoots WK, Pipe SW, Rivard GE, Santagostino E International workshop on immune tolerance induction: consensus recommendations. Haemophilia 2007, 13(Suppl. 1):1-22.
5. Nilsson IM, Hedner U, Björlin G Suppression of factor IX antibody in hemophilia B by factor IX and cyclophosphamide. Ann Intern Med 1973, 78:91-95.
6. Fekete LF, Holst SL, Peetoom F, De Veber LL. "Auto" factor IX concentrate: a new therapeutic approach to treatment of hemophilia A patients with inhibitors. 1972.
7. Lusher JM, Shapiro SS, Palascak JE, Rao AV, Levine PH, Blatt PM Efficacy of prothrombin-complex concentrates in hemophiliacs with antibodies to factor VIII: a multicenter therapeutic trial. N Engl J Med 1980, 303:421-425.
8. Sjamsoedin LJ, Heijnen L, Mauser-Bunschoten EP, van Geijlswijk JL, van Houwelingen H, van Asten P, et al. The effect of activated prothrombin-complex concentrate (FEIBA) on joint and muscle bleeding in patients with hemophilia A and antibodies to factor VIII. A double-blind clinical trial. N Engl J Med 1981, 305:717-721.
9. Young G, Shafer FE, Rojas P, Seremetis S Single 270 microg kg(-1)-dose rFVIIa vs. standard 90 microg kg(-1)-dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison. Haemophilia 2008, 14:287-294.
10. Blatt PM, Lundblad RL, Kingdon HS, McLean G, Roberts HR Thrombogenic materials in prothrombin complex concentrates. Ann Intern Med 1974, 81:766-770.
11. Davey RJ, Shashaty GG, Rath CE Acute coagulopathy following infusion of prothrombin complex concentrate. Am J Med 1976, 60:719-722.
12. Edson JR Letter: Prothrombin-complex concentrates and thrombosis. N Engl J Med 1972, 290:403-404.
13. Kasper CK Postoperative thromboses in hemophilia B. N Engl J Med 1973, 289:160.
14. Kasper CK Thromboembolic complications. Thromb Diath Haemorrh 1975, 33:640-644.
15. Kingdon HS, Lundblad RL, Veltkamp JJ, Aronson DL Potentially thrombogenic materials in factor IX concentrates. Thromb Diath Haemorrh 1975, 33:617-631.
16. Marchesi SL, Burney R Letter: Prothrombin-complex concentrates and thrombosis. N Engl J Med 1974, 490:403-404.
17. Steinberg MH, Breiling BJ Vascular lesions in hemophilia B. N Engl J Med 1973, 289:592.
18. Hilgartner MW, Knatterud GL The use of factor eight inhibitor by-passing activity (FEIBA immuno) product for treatment of bleeding episodes in hemophiliacs with inhibitors. Blood 1983, 61:36-40.
19. Kasper CK, Feinstein DI Letter: Rising factor VIII inhibitor titers after Konyne factor IX complex. N Engl J Med 1976, 295:505-506.
20. Stenbjerg S, Jørgensen J Activated F IX concentrate (FEIBA) used in the treatment of haemophilic patients with antibody to F VIII. Acta Med Scand 1978, 203:471-476.
21. Blajchman MA, Vamvakas EC The continuing risk of transfusion-transmitted infections. N Engl J Med 2006, 355:1303-1305.
22. Dolan G Clinical implications of emerging pathogens in haemophilia: the variant Creutzfeldt-Jakob disease experience. Haemophilia 2006, 12(Suppl. 1):16-20.
23. Ironside JW Variant Creutzfeldt-Jakob disease: risk of transmission by blood transfusion and blood therapies. Haemophilia 2006, 12(Suppl. 1):8-15.
24. Pipe SW The physician's role in selecting a factor replacement therapy. Haemophilia 2006, 12(Suppl. 1):21-25.
25. Tapper ML Emerging viral diseases and infectious disease risks. Haemophilia 2006, 12(Suppl. 1):3-7.
26. Hedner U, Nilsson IM, Bergentz SE Various prothrombin complex concentrates and their effect on coagulation and fibrinolysis in vivo. Thromb Haemost 1976, 35:386-395.
27. Hedner U, Nilsson IM, Bergentz SE Studies on the thrombogenic activities in two prothrombin complex concentrates. Thromb Haemost 1979, 42:1022-1032.
28. Hedner U, Kisiel W Use of human factor VIIa in the treatment of two hemophilia A patients with high-titer inhibitors. J Clin Invest 1983, 71:1836-1841.
29. Hedner U, Bjoern S, Bernvil SS, Tengborn L, Stigendahl L Clinical experience with human plasma-derived factor VIIa in patients with hemophilia A and high titer inhibitors. Haemostasis 1989, 19:335-343.
30. Hagen FS, Gray CL, O'Hara P, Grant FJ, Saari GC, Woodbury RG, et al. Characterization of a cDNA coding for human factor VII. Proc Natl Acad Sci U S A 1986, 83:2412-2416.
31. Jurlander B, Thim L, Klausen NK, Persson E, Kjalke M, Rexen P, et al. Recombinant activated factor VII (rFVIIa): characterization, manufacturing, and clinical development. Semin Thromb Hemost 2001, 27:373-384.
32. Bjoern S, Thim L Activation of coagulation factor VII to VIIa. Research Disclosure 1986, 269:564-565.
33. Bjoern S, Foster DC, Thim L, Wiberg FC, Christensen M, Komiyama Y, et al. Human plasma and recombinant factor VII. Characterization of O-glycosylations at serine residues 52 and 60 and effects of site-directed mutagenesis of serine 52 to alanine. J Biol Chem 1991, 266:11051-11057.
34. Klausen NK, Bayne S, Palm L Analysis of the site-specific asparagine-linked glycosylation of recombinant human coagulation factor VIIa by glycosidase digestions, liquid chromatography, and mass spectrometry. Mol Biotechnol 1998, 9:195-204.
35. Thim L, Bjoern S, Christensen M, Nicolaisen EM, Lund-Hansen T, Pedersen AH, et al. Amino acid sequence and posttranslational modifications of human factor VIIa from plasma and transfected baby hamster kidney cells. Biochemistry 1988, 27:7785-7793.
36. Brinkhous KM, Hedner U, Garris JB, Diness V, Read MS Effect of recombinant factor VIIa on the hemostatic defect in dogs with hemophilia A, hemophilia B, and von Willebrand disease. Proc Natl Acad Sci U S A 1989, 86:1382-1386.
37. Diness V, Lund-Hansen T, Hedner U Effect of recombinant human FVIIA on warfarin-induced bleeding in rats. Thromb Res 1990, 59:921-929.
38. Diness V, Bregengaard C, Erhardtsen E, Hedner U Recombinant human factor VIIa (rFVIIa) in a rabbit stasis model. Thromb Res 1992, 67:233-241.
39. Erhardtsen E Pharmacokinetics of recombinant activated factor VII (rFVIIa). Semin Thromb Hemost 2000, 26:385-391.
40. Hedner U, Kristensen H, Berntorp E, Ljung R, Petrini P, Tengborn L Pharmacokinetics of rFVIIa in children. Haemostasis 1988, 4. Abstract 355.
41. Lindley CM, Sawyer WT, Macik BG, Lusher J, Harrison JF, Baird-Cox K, et al. Pharmacokinetics and pharmacodynamics of recombinant factor VIIa. Clin Pharmacol Ther 1994, 55:638-648.
42. Hedner U, Glazer S, Pingel K, Alberts KA, Blomback M, Schulman S, et al. Successful use of recombinant factor VIIa in patient with severe haemophilia A during synovectomy. Lancet 1988, 2:1193.
43. Macik BG, Hohneker J, Roberts HR, Griffin AM Use of recombinant activated factor VII for treatment of a retropharyngeal hemorrhage in a hemophilic patient with a high titer inhibitor. Am J Hematol 1989, 32:232-234.
44. Hedner U Factor VIIa in the treatment of haemophilia. Blood Coagul Fibrinolysis 1990, 1:307-317.
45. Hedner U, Lund-Hansen T, Winther D Comparison of the effect of factor VII preparted from human plasma (pVIIa) and recombinant VIIa (rVIIa) in vitro and in rabbits. Transfusion 1987, 58:270.
46. Telgt DS, Macik BG, McCord DM, Monroe DM, Roberts HR Mechanism by which recombinant factor VIIa shortens the aPTT: activation of factor X in the absence of tissue factor. Thromb Res 1989, 56:603-609.
47. Rao LV, Rapaport SI Factor VIIa-catalyzed activation of factor X independent of tissue factor: its possible significance for control of hemophilic bleeding by infused factor VIIa. Blood 1990, 75:1069-1073.
48. Monroe DM, Roberts HR, Hoffman M Platelet procoagulant complex assembly in a tissue factor-initiated system. Br J Haematol 1994, 88:364-371.
49. Monroe DM, Hoffman M, Oliver JA, Roberts HR Platelet activity of high-dose factor VIIa is independent of tissue factor. Br J Haematol 1997, 99:542-547.
50. Monroe DM, Hoffman M, Roberts HR Platelets and thrombin generation. Arterioscler Thromb Vasc Biol 2002, 22:1381-1389.
51. Blombäck B Fibrinogen and fibrin-proteins with complex roles in hemostasis and thrombosis. Thromb Res 1996, 83:1-75.
52. Hedner U Factor VIIa and its potential therapeutic use in bleeding-associated pathologies. Thromb Haemost 2008, 100:557-562.
53. Allen GA, Wolberg AS, Oliver JA, Hoffman M, Roberts HR, Monroe DM Impact of procoagulant concentration on rate, peak and total thrombin generation in a model system. J Thromb Haemost 2004, 2:402-413.
54. He S, Blombäck M, Jacobsson EG, Hedner U The role of recombinant factor VIIa (FVIIa) in fibrin structure in the absence of FVIII/FIX. J Thromb Haemost 2003, 1:1215-1219.
55. Augustsson C, Persson E In vitro evidence of a tissue factor-independent mode of action of recombinant factor VIIa in hemophilia. Blood 2014, 124:3172-3174.
56. Feng D, Whinna H, Monroe D, Stafford DW FVIIa as used pharmacologically is not TF dependent in hemophilia B mice. Blood 2014, 123:1764-1766.
57. Konkle BA, Ebbesen LS, Erhardtsen E, Bianco RP, Lissitchkov T, Rusen L, et al. Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors. J Thromb Haemost 2007, 5:1904-1913.
58. Clark CA, Vatsyayan R, Hedner U, Esmon CT, Pendurthi UR, Rao LV Endothelial cell protein C receptor-mediated redistribution and tissue-level accumulation of factor VIIa. J Thromb Haemost 2012, 10:2383-2391.
59. Gopalakrishnan R, Hedner U, Ghosh S, Nayak RC, Allen TC, Pendurthi UR, et al. Bio-distribution of pharmacologically administered recombinant factor VIIa (rFVIIa). J Thromb Haemost 2010, 8:301-310.
60. Gopalakrishnan R, Hedner U, Clark C, Pendurthi UR, Rao LV rFVIIa transported from the blood stream into tissues is functionally active. J Thromb Haemost 2010, 8:2318-2321.
61. Zatta A, Mcquilten Z, Kandane-Rathnayake R, Isbister J, Dunkley S, Mcneil J, et al. The Australian and New Zealand Haemostasis Registry: ten years of data on off-licence use of recombinant activated factor VII. Blood Transfus 2015, 13:86-99.
62. Kenet G, Walden R, Eldad A, Martinowitz U Treatment of traumatic bleeding with recombinant factor VIIa. Lancet 1999, 354:1879.
63. Mohr AM, Holcomb JB, Dutton RP, Duranteau J Recombinant activated factor VIIa and hemostasis in critical care: a focus on trauma. Crit Care 2005, 9(Suppl. 5):S37-S42.
64. Rossaint R, Bouillon B, Cerny V, Coats TJ, Duranteau J, Fernandez-Mondejar E, et al. Management of bleeding following major trauma: an updated European guideline. Crit Care 2010, 14:R52.
65. Vincent JL, Rossaint R, Riou B, Ozier Y, Zideman D, Spahn DR Recommendations on the use of recombinant activated factor VII as an adjunctive treatment for massive bleeding - a European perspective. Crit Care 2006, 10:R120.
66. Boffard KD, Riou B, Warren B, Choong PI, Rizoli S, Rossaint R, et al. Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo-controlled, double-blind clinical trials. J Trauma 2005, 59:8-15.
67. Mayer SA, Brun NC, Begtrup K, Broderick J, Davis S, Diringer MN, et al. Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 2005, 352:777-785.
68. Mayer SA, Brun NC, Begtrup K, Broderick J, Davis S, Diringer MN, et al. Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 2008, 358:2127-2137.
69. Villar A, Aronis S, Morfini M, Santagostino E, Auerswald G, Thomsen HF, et al. Pharmacokinetics of activated recombinant coagulation factor VII (NovoSeven) in children vs. adults with haemophilia A. Haemophilia 2004, 10:352-359.
70. Kavakli K, Makris M, Zulfikar B, Erhardtsen E, Abrams ZS, Kenet G Home treatment of haemarthroses using a single dose regimen of recombinant activated factor VII in patients with haemophilia and inhibitors. A multicentre, randomised, double-blind, cross-over trial. Thromb Haemost 2006, 95:600-605.
71. Kjalke M, Ezban M, Monroe DM, Hoffman M, Roberts HR, Hedner U High-dose factor VIIa increases initial thrombin generation and mediates faster platelet activation in thrombocytopenia-like conditions in a cell-based model system. Br J Haematol 2001, 114:114-120.
72. Poon MC, Demers C, Jobin F, Wu JW Recombinant factor VIIa is effective for bleeding and surgery in patients with Glanzmann thrombasthenia. Blood 1999, 94:3951-3953.
73. Tengborn L, Petruson B A patient with Glanzmann thrombasthenia and epistaxis successfully treated with recombinant factor VIIa. Thromb Haemost 1996, 75:981-982.
74. Poon MC, D'Oiron R, Von Depka M, Khair K, Négrier C, Karafoulidou A, et al. Prophylactic and therapeutic recombinant factor VIIa administration to patients with Glanzmann's thrombasthenia: results of an international survey. J Thromb Haemost 2004, 2:1096-1103.
75. ® summary of product characteristics [Accessed July 23, 2014]. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000074/WC500030873.pdf.
76. Poon MC Clinical use of recombinant human activated factor VII (rFVIIa) in the prevention and treatment of bleeding episodes in patients with Glanzmann's thrombasthenia. Vasc Health Risk Manag 2007, 3:655-664.
77. Brenner B, Wiis J Experience with recombinant-activated factor VII in 30 patients with congenital factor VII deficiency. Hematology 2007, 12:55-62.
78. Mariani G, Konkle BA, Ingerslev J Congenital factor VII deficiency: therapy with recombinant activated factor VII - a critical appraisal. Haemophilia 2006, 12:19-27.